Organon supplements proxy with $700M synergy estimate; shareholder lawsuit seeks to delay merger vote

Organon & Co.

Shareholder lawsuit filed July 6 in NJ Superior Court alleges proxy disclosures are materially incomplete and misleading.
Company voluntarily supplements proxy with preliminary cost synergy estimate of ~$700M from Sun Pharma transaction.
Provides financial projections: 2026E revenue $6,252M, Adj EBITDA $1,894M, unlevered FCF $1,010M.
Net debt $7,530M, fully diluted shares ~284.9M as of April 24, 2026; LTM Adj EBITDA $1,832M.
Special meeting of stockholders to vote on merger remains scheduled for July 23, 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.